Literature DB >> 1972485

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

M Galli1, P Comfurius, C Maassen, H C Hemker, M H de Baets, P J van Breda-Vriesman, T Barbui, R F Zwaal, E M Bevers.   

Abstract

The binding of affinity-purified anticardiolipin antibodies (ACA) to liposomes that contained cardiolipin or phosphatidylserine was investigated. ACA bound to these liposomes only in the presence of plasma or serum, which indicated a requirement for a plasma component. This component--referred to as aca-cofactor--was purified; its activity to support ACA binding to liposomes that contained cardiolipin was not destroyed by heat (10 min at 90 degrees C), but was greatly diminished on incubation with trypsin. aca-cofactor bound liposomes that contained negatively charged phospholipid but had no affinity for liposomes that contained neutral phospholipid (eg, phosphatidylcholine); this binding was independent of calcium ions. aca-cofactor was essential for ACA to bind to liposomes that contained cardiolipin or phosphatidylserine and, when coated on a microtitre plate in the absence of any phospholipid, aca-cofactor was an apparent antigen for ACA in an enzyme-linked immunosorbent assay. aca-cofactor is a single chain polypeptide with an apparent molecular weight of 50 kD (non-reduced), which increases to 70 kD upon reduction, and its properties closely resemble those of beta 2-glycoprotein I (apolipoprotein H).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972485     DOI: 10.1016/0140-6736(90)91374-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  173 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

2.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 3.  Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis?

Authors:  M Hoffman; D M Monroe; R A Roubey
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

4.  Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

Authors:  M Blank; Y Shoenfeld; S Cabilly; Y Heldman; M Fridkin; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 5.  Antiphospholipid antibodies and cardiovascular disease.

Authors:  H L Beynon; M J Walport
Journal:  Br Heart J       Date:  1992-04

Review 6.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 7.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 8.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 9.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

10.  Evaluation of serum anti-cardiolipin antibodies after non-surgical periodontal treatment in chronic periodontitis patients.

Authors:  Farin Kiany; Azita Hedayati
Journal:  Odontology       Date:  2014-02-14       Impact factor: 2.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.